Thorough Future

Thorough Future (透彻未来) is a Chinese pathology AI company and a Qiming Venture Partners portfolio company, described by Qiming as a leading player in discriminative pathology AI diagnosis . Its core product, Thorough Insights (透彻洞察), is a pathology AI-assisted diagnostic platform that — per Qiming's July 2026 update — has been deployed in over a thousand medical institutions globally . Recent milestones include a partnership with Astellas China on AI-powered precision diagnosis of gastric cancer , a multimodal weakly-supervised learning study on advanced EGFR-mutant non-small-cell lung cancer with Beijing Chest Hospital published in the Journal of Translational Medicine , and spots on the AI Top 10 at the Zhongguancun Frontier Tech Competition, KPMG China's Biotech Innovation 50, and VBData's 2026 Future Healthcare 100 . Founding details and financing history aren't covered in elsewhere's corpus.